Logo

American Heart Association

  142
  0


Final ID:

Discussant: ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis

  • Nativi-nicolau, Jose  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Author Disclosures:
    Jose Nativi-Nicolau: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

More abstracts on this topic:
Discussant: OLE & HELIOS-B

Grogan Martha, Kittleson Michelle, Nair Ajith, Grodin Justin, Ambardekar Amrut

The prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure: The Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations Study

Ruberg Frederick, Blaner William, Deluca Albert, Johnson Lynne, Kinkhabwala Mona, Leb Jay, Mintz Akiva, Lavalley Michael, Einstein Andrew, Cohn Elizabeth, Kelly Jeffery, Teruya Sergio, Miller Edward, Maurer Mathew, Helmke Stephen, Fine Denise, Kurian Damian, Raiszadeh Farbod, Connors Lawreen, Prokaeva Tatiana, Pandey Shivda

More abstracts from these authors:
Evolving Baseline Risk in Patients With Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials

Masri Ahmad, Nativi-nicolau Jose, Wright Richard, Betts Marissa, Lavoie Louis, Shree Aiswarya, Hennum Liana, Tamby Jean-francois, Falvey Heather, Dev Sandesh

Red Flags in New Onset HFpEF that Should Raise Suspicion for Cardiac Amyloidosis

Alexander Kevin, Nativi-nicolau Jose, Raymer David

You have to be authorized to contact abstract author. Please, Login
Not Available